Skip to search formSkip to main contentSkip to account menu

MP470

Known as: HPK56, MP-470 
National Institutes of Health

Related topics

Related topics

3 relations
Amuvatinib Hydrochloride

Broader (1)

Pyrimidines

Narrower (1)

amuvatinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A phase Ib dose-escalation study of orally administered MP-470, a multi-kinase inhibitor and supressor of Rad51, in combination with carboplatin doublet containing regimens shows activity in highly…
e13511 Background: MP-470 (MP) is an oral multi-targeted tyrosine kinase inhibitor which inhibits a number of validated tumor… 
2013
2013
Abstract 2095: A phase 2 study of Amuvatinib (MP-470), the first RAD51 inhibitor in combination with platinum-etoposide (PE) in refractory or relapsed small cell lung cancer (ESCAPE).
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Background: Amuvatinib is an oral multi-targeted TKI… 
2011
2011
Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA repair: Final results from a 100-patient, 5-arm phase Ib trial in combination with five standard of care (SOC) anticancer…
3074 Background: Amuvatinib is an oral multi-targeted TKI which inhibits the mutant forms of c-kit, and PDGFRα. It also disrupts… 
2010
2010
171 Amuvatinib (MP-470), a multi-targeted tyrosine kinase inhibitor and DNA repair suppressor, synergizes with etoposide (VP-16) in small cell lung cancer (SCLC) cell lines and xenografts
2010
2010
193 Effects of combining amuvatinib (MP-470) with DNA-damaging agents in osteosarcoma cell lines
2010
2010
Abstract 2749: MP-470, a dual inhibitor of mutant kinases (c-KIT and PDGFRα) and DNA repair protein Rad 51. Final results from a first-in-man single agent study
Background: MP-470 is an orally bioavailable multi-targeted tyrosine kinase inhibitor specifically designed to be a potent… 
2009
2009
135P A PHASE 1B DOSE ESCALATION STUDY OF MP-470 ADMINISTERED CONCURRENTLY WITH STANDARD OF CARE CHEMOTHERAPY IN PATIENTS WITH NSCLC AND SCLC
2009
2009
Gateways to clinical trials.
(-)-Gossypol; Abacavir sulfate/lamivudine, ACAM-1000, ACE-011, Agomelatine, AGS-004, Alemtuzumab, Alvocidib hydrochloride, AMG… 
2008
2008
426 POSTER Effects of food on the single-dose pharmacokinetics of oral MP-470 capsules
2008
2008
403 POSTER Clinical responses in highly refractory solid tumor patients with oral MP-470, a multi-targeted tyrosine kinase inhibitor, in combination with standard of care chemotherapy regimens…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)